Investigating the prescribing trajectory and geographical drug utilisation patterns of gabapentinoids in primary care in England: an ecological studyCitation formats

Standard

Harvard

APA

Vancouver

Author

Bibtex

@article{e4b7535e47764f8195a7d9b8544747b2,
title = "Investigating the prescribing trajectory and geographical drug utilisation patterns of gabapentinoids in primary care in England: an ecological study",
abstract = "AimThis study aimed to investigate the prescribing trajectory, geographical variation and population factors including the socioeconomic status (SES) related to prescribing gabapentinoids in primary care in England.MethodsThis ecological study applied practice-level dispensing data and statistics from the UK National Health Service Digital and Office for National Statistics from 2013-2019. The prescribing of gabapentinoids (in defined daily doses (DDDs)/1000 people) was measured annually and quarterly. General practices were categorised according to the quarterly prescribing in a group-based trajectory model. The one-year prescribing in 2018/19 was associated with practice-level covariates in a mixed-effects multilevel regression; adjusted for the cluster-effects of Clinical Commissioning Groups (CCGs) and mapped geographically.ResultsThe annual national prescription rate increased by 70% from 2800 to 4773 DDDs/1000 people in the time period 2013/14 to 2018/19. General practices were stratified into six trajectory groups. Practices with the highest level and the greatest increase in prescribing (n=792; 9.8%) are mainly located in the north of England and along the east and south coastline. Socioeconomic status, demographic characteristics and relevant disease conditions were significantly associated with the prescribing. For every decrease in the Index of Multiple Deprivation decile (becoming less affluent), prescribing of gabapentinoids significantly increased by 203 (95%CI: 183, 222) DDDs/1000 registrants. ConclusionGabapentinoid prescribing trajectories varied across geographical regions and are associated with socioeconomic status, CCG locality (geography) and other population characteristics. These factors should be considered in future studies investigating the determinants of gabapentinoid prescribing and the risk of harms associated with gabapentinoids. ",
author = "Xinchun Gu and Teng-Chou Chen and Ting-Li Su and Douglas Steinke and Li-Chia Chen",
year = "2021",
month = may,
day = "3",
doi = "10.1111/bcp.14827",
language = "English",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "John Wiley & Sons Ltd",

}

RIS

TY - JOUR

T1 - Investigating the prescribing trajectory and geographical drug utilisation patterns of gabapentinoids in primary care in England: an ecological study

AU - Gu, Xinchun

AU - Chen, Teng-Chou

AU - Su, Ting-Li

AU - Steinke, Douglas

AU - Chen, Li-Chia

PY - 2021/5/3

Y1 - 2021/5/3

N2 - AimThis study aimed to investigate the prescribing trajectory, geographical variation and population factors including the socioeconomic status (SES) related to prescribing gabapentinoids in primary care in England.MethodsThis ecological study applied practice-level dispensing data and statistics from the UK National Health Service Digital and Office for National Statistics from 2013-2019. The prescribing of gabapentinoids (in defined daily doses (DDDs)/1000 people) was measured annually and quarterly. General practices were categorised according to the quarterly prescribing in a group-based trajectory model. The one-year prescribing in 2018/19 was associated with practice-level covariates in a mixed-effects multilevel regression; adjusted for the cluster-effects of Clinical Commissioning Groups (CCGs) and mapped geographically.ResultsThe annual national prescription rate increased by 70% from 2800 to 4773 DDDs/1000 people in the time period 2013/14 to 2018/19. General practices were stratified into six trajectory groups. Practices with the highest level and the greatest increase in prescribing (n=792; 9.8%) are mainly located in the north of England and along the east and south coastline. Socioeconomic status, demographic characteristics and relevant disease conditions were significantly associated with the prescribing. For every decrease in the Index of Multiple Deprivation decile (becoming less affluent), prescribing of gabapentinoids significantly increased by 203 (95%CI: 183, 222) DDDs/1000 registrants. ConclusionGabapentinoid prescribing trajectories varied across geographical regions and are associated with socioeconomic status, CCG locality (geography) and other population characteristics. These factors should be considered in future studies investigating the determinants of gabapentinoid prescribing and the risk of harms associated with gabapentinoids.

AB - AimThis study aimed to investigate the prescribing trajectory, geographical variation and population factors including the socioeconomic status (SES) related to prescribing gabapentinoids in primary care in England.MethodsThis ecological study applied practice-level dispensing data and statistics from the UK National Health Service Digital and Office for National Statistics from 2013-2019. The prescribing of gabapentinoids (in defined daily doses (DDDs)/1000 people) was measured annually and quarterly. General practices were categorised according to the quarterly prescribing in a group-based trajectory model. The one-year prescribing in 2018/19 was associated with practice-level covariates in a mixed-effects multilevel regression; adjusted for the cluster-effects of Clinical Commissioning Groups (CCGs) and mapped geographically.ResultsThe annual national prescription rate increased by 70% from 2800 to 4773 DDDs/1000 people in the time period 2013/14 to 2018/19. General practices were stratified into six trajectory groups. Practices with the highest level and the greatest increase in prescribing (n=792; 9.8%) are mainly located in the north of England and along the east and south coastline. Socioeconomic status, demographic characteristics and relevant disease conditions were significantly associated with the prescribing. For every decrease in the Index of Multiple Deprivation decile (becoming less affluent), prescribing of gabapentinoids significantly increased by 203 (95%CI: 183, 222) DDDs/1000 registrants. ConclusionGabapentinoid prescribing trajectories varied across geographical regions and are associated with socioeconomic status, CCG locality (geography) and other population characteristics. These factors should be considered in future studies investigating the determinants of gabapentinoid prescribing and the risk of harms associated with gabapentinoids.

U2 - 10.1111/bcp.14827

DO - 10.1111/bcp.14827

M3 - Article

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

ER -